Octozi raises $3M seed to automate clinical trial data operations with agentic AI
The AMW Read
Novelty 2 because Octozi is a new entrant with published trial data rare at seed stage, updating the Healthcare/Bio player map; significance 1 because $3M seed is sub-segment scale but the evidence-based go-to-market is notable.
Octozi raises $3M seed to automate clinical trial data operations with agentic AI
Octozi, a New York-based AI company focused on clinical development workflows, announced a $3 million seed round led by Surface Ventures, with participation from Remarkable Ventures and Debiopharm's venture arm. The company's platform integrates large language models with deterministic clinical algorithms and external medical knowledge to automate data cleaning, reconciliation, review, and reporting for pharmaceutical sponsors. In a controlled study, Octozi reported a six-fold increase in data cleaning throughput, a reduction in reviewer error rate from 54.7% to 8.5%, and an estimated $5 million savings per Phase III oncology trial.
Why it matters: This funding exemplifies the emerging pattern of vertical agentic AI in regulated enterprise verticals — what the AMW substrate frames as context-engineering moats built on domain-specific deterministic rules overlaid by LLMs. Octozi's human-in-the-loop architecture targeting late-stage (Phase III) trials places it squarely in the slow, high-stakes data operations layer of drug development, a segment that has seen minimal automation adoption. The published error-rate reduction and cost savings data give it a defensible evidence base rare at the seed stage, potentially accelerating enterprise procurement cycles among risk-averse pharmaceutical sponsors.
The clinical data operations segment sits at the intersection of healthcare AI and agentic workflow automation. Surface Ventures' emphasis on regulatory data quality and time-to-market for therapies suggests the investment thesis aligns with the broader capital-cycle rebalancing toward vertical SaaS that generates measurable ROI rather than horizontal platform bets. Octozi's partnership with Debiopharm's venture arm further provides a pharma insider's validation and potential pipeline for commercial deployment.